

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/077869 A2

- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number: PCT/US03/07994
- (22) International Filing Date: 14 March 2003 (14.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:

60/364,140	15 March 2002 (15.03.2002)	US
60/319,846	9 January 2003 (09.01.2003)	US

22102 (US). **TEPER, Gary, L.**; 13 Candlelight Court, Potomac, MD 20854 (US). **GREESON, Janet**; 2877 Paradise Road, Suite 801, Las Vegas, NC 89109 (US). **PAPADOPOULOS, Vassilios**; 15417 Peach Leaf Drive, North Potomac, MD 20878 (US).

(74) Agents: **MAHONEY, Joseph** et al.; Mayer Brown Rowe & Maw, P.O. Box 2828, Chicago, IL 60690-2828 (US).

(71) Applicants: **SAMARITAN PHARMACEUTICALS, INC** [US/US]; 101 Convention center, Suite 210, las Vegas, NV 89109 (US). **GEORGETOWN UNIVERSITY** [US/US]; 37th & O Streets, N.W., Washington, DC 20057 (US).


(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(72) Inventors: **YAO, Zhi-Xing**; 1415 N. Oak St, No. 604, Arlington, VA 22209 (US). **LECANU, Laurent**; 8370 Greensboror Dr., Building #4, Apt. 706, Mclean, VA

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NEUROPROTECTIVE SPIROSTENOL PHARMACEUTICAL COMPOSITIONS



(57) Abstract: The present invention relates to methods, kits, combinations, and compositions for treating, preventing or reducing the risk of developing a disorder or disease related to, or the symptoms associated with, neurotoxicity in a subject, particularly to beta-amyloid-induced neurotoxicity and Alzheimer's disease. The compounds of the present invention are biologically active 22R-hydroxycholesterol derivatives containing a common spirost-5-en-3-ol structure. The invention further provides a method for treating a patient having a neurological disease or disorder such as global and focal ischemic and hemorrhagic stroke, head trauma, spinal cord injury, hypoxia-induced nerve cell damage, nerve cell damage caused by cardiac arrest or neonatal distress, epilepsy, anxiety, diabetes mellitus, multiple sclerosis, phantom limb pain, causalgia, neuralgias, herpes zoster, spinal cord lesions, hyperalgesia, allodynia, Huntington's disease, and Parkinson's disease, by administering to the patient a therapeutically effective amount of 22R-hydroxycholesterol or a therapeutically active analog thereof.



WO 03/077869 A2